Tekedia Capital is excited to announce our investment in Anto Biosciences, a company building foundation models for microbial communities and making the gut microbiome computable for the first time.
Over one billion people take medications whose success or failure is influenced by the gut microbiome. Yet modern drug development largely treats the microbiome as noise. But it is not noise; it is signal.
The human gut hosts trillions of microorganisms that influence how drugs are absorbed, metabolized, and tolerated. Two patients can take the same medication, at the same dosage, for the same condition, and experience entirely different outcomes because their microbial communities differ. Hidden within these differences lies one of medicine’s greatest unsolved problems: why do drugs work for some people and fail for others? Anto believes the answer lies in computation. Yes, everything is numbers and computation unlocks everything, extrapolating from Pythagoras!
Register for Tekedia Mini-MBA edition 20 (June 8 – Sept 5, 2026).
Register for Tekedia AI in Business Masterclass.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Register for Tekedia AI Lab.
The company has pioneered quality-aware, goal-directed sparsification algorithms. Microbiome data is notoriously complex and noisy, approximately 99% of the data may carry little predictive value. Anto removes the noise and isolates the small fraction that contains meaningful biological signals, making the microbiome computationally tractable.
Building on this foundation, Anto invented its Darwin model series to predict drug toxicity and efficacy across diverse populations and helps optimize molecules for broader therapeutic success.
Why did Tekedia Capital invest? In business and science, breakthroughs often occur when someone transforms what appears chaotic into something computable. The transistor made electricity computable. The database made information computable. Foundation models are making language computable. Anto seeks to make microbial communities computable!
If successful, this company could fundamentally reshape drug discovery, precision medicine, and therapeutics by ensuring that medicines work not merely for average patients, but for humanity in all its biological diversity.
Anto was founded by an exceptional team: Arvid from the Broad Institute of MIT and Harvard, a Nature-published researcher who pioneered quality-aware, goal-directed sparsification, and David from Harvard Medical School Gastroenterology and Johnson & Johnson. Together, these second-time founders have published their breakthroughs in leading machine learning conferences and premier scientific journals. On behalf of Tekedia Capital, I welcome Anto Biosciences to Tekedia Capital.
---
Connect via my
LinkedIn |
Facebook |
X |
YouTube
